Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 4/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | GAK | O14976 | 7/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.49 |
| ▸ | COQ8A | Q8NI60 | 4/20 | 0.49 |
| ▸ | NLK | Q9UBE8 | 4/20 | 0.49 |
| ▸ | SRC | P12931 | 3/20 | 0.49 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.49 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.49 |
| ▸ | EPHA8 | P29322 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2063370 | 0.92 | EGFR (0.56) | RETEGFRPDGFRAGAKRIPK2 | |
| SCHEMBL4376291 | 0.83 | RET (0.84) | RETEGFRGAKRIPK2LCK | |
| SCHEMBL6046159 | 0.75 | EGFR (0.75) | RETEGFRPDGFRAGAKRIPK2 | |
| SCHEMBL4383397 | 0.74 | RET (0.70) | RETEGFRGAKRIPK2LCK | |
| SCHEMBL2063094 | 0.74 | EGFR (0.53) | RETEGFRPDGFRAGAKRIPK2 | |
| Hydrochloric Acid SCHEMBL6432540 | 0.74 | RET (0.68) | RETEGFRPDGFRAGAKRIPK2 | |
| SCHEMBL6434027 | 0.74 | EGFR (0.72) | RETEGFRPDGFRAGAKRIPK2 | |
| Hydrochloric Acid SCHEMBL4377353 | 0.74 | RET (0.69) | RETEGFRGAKRIPK2LCK | |
| SCHEMBL2063817 | 0.73 | EGFR (0.55) | RETEGFRPDGFRAGAKRIPK2 | |
| SCHEMBL2062952 | 0.73 | EGFR (0.52) | RETEGFRPDGFRAGAKRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004017-A1 | Quinazoline derivatives as angiogenesis inhibitors | FLT4, NOS3, FLT1 | RET 1047/4885EGFR 549/4885PDGFRA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.